BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, Velasco J, Majdan M, Irazoque-Palazuelos F, Weiswasser M, Korish S, Ye Y, Gaudy A, Schafer PH, Liu Z, Agafonova N, Delev N. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med 2022;386:1034-45. [PMID: 35294813 DOI: 10.1056/NEJMoa2106535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Lichtnekert J, Anders H, Lech M. Lupus Nephritis: Current Perspectives and Moving Forward. JIR 2022;Volume 15:6533-6552. [DOI: 10.2147/jir.s363722] [Reference Citation Analysis]
2 Crow MK. Advances in lupus therapeutics: Achieving sustained control of the type I interferon pathway. Current Opinion in Pharmacology 2022;67:102291. [DOI: 10.1016/j.coph.2022.102291] [Reference Citation Analysis]
3 Yap DYH, Mok CC. Novel and emerging treatment strategies for lupus nephritis. Expert Rev Clin Pharmacol 2022. [PMID: 36260817 DOI: 10.1080/17512433.2022.2138340] [Reference Citation Analysis]
4 Guo H, Yang J, Wang H, Liu X, Liu Y, Zhou K. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Front Immunol 2022;13:1017990. [DOI: 10.3389/fimmu.2022.1017990] [Reference Citation Analysis]
5 Moysidou G, T. Boumpas D. Targeted Therapies for Systemic Lupus Erythematosus (SLE): A Critical Appraisal. Systemic Lupus Erythematosus - Pathogenesis and Management [Working Title] 2022. [DOI: 10.5772/intechopen.105811] [Reference Citation Analysis]
6 Arbitman L, Furie R, Vashistha H. B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun 2022;:102873. [PMID: 35963808 DOI: 10.1016/j.jaut.2022.102873] [Reference Citation Analysis]
7 Boulougoura A, Tsokos GC. Ikaros, Aiolos and other moving targets to treat SLE. Nat Rev Rheumatol 2022. [PMID: 35831638 DOI: 10.1038/s41584-022-00815-2] [Reference Citation Analysis]
8 Sprow G, Dan J, Merola JF, Werth VP. Emerging Therapies in Cutaneous Lupus Erythematosus. Front Med 2022;9. [DOI: 10.3389/fmed.2022.968323] [Reference Citation Analysis]
9 Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. Nat Med 2022. [PMID: 35788174 DOI: 10.1038/s41591-022-01880-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Weninger W. Maske rauf, Maske runter. hautnah 2022;21:64-65. [DOI: 10.1007/s12326-022-00516-3] [Reference Citation Analysis]
11 Lipsky PE, Vollenhoven RV, Dörner T, Werth VP, Merrill JT, Furie R, Petronijevic M, Velasco Zamora B, Majdan M, Irazoque-Palazuelos F, Terbrueggen R, Delev N, Weiswasser M, Korish S, Stern M, Hersey S, Ye Y, Gaudy A, Liu Z, Gagnon R, Tang S, Schafer PH. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann Rheum Dis 2022:annrheumdis-2022-222212. [PMID: 35477518 DOI: 10.1136/annrheumdis-2022-222212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nikolopoulos D, Fotis L, Gioti O, Fanouriakis A. Tailored treatment strategies and future directions in systemic lupus erythematosus. Rheumatol Int 2022. [PMID: 35449237 DOI: 10.1007/s00296-022-05133-0] [Reference Citation Analysis]
13 Costenbader KH. A New IMiD for Systemic Lupus Erythematosus - Tempering Our Excitement. N Engl J Med 2022;386:1085-6. [PMID: 35294819 DOI: 10.1056/NEJMe2201329] [Reference Citation Analysis]